(NASDAQ: CRMD) Cormedix's forecast annual revenue growth rate of 28.5% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.3%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.86%.
Cormedix's revenue in 2025 is $214,303,672.On average, 9 Wall Street analysts forecast CRMD's revenue for 2025 to be $24,931,217,509, with the lowest CRMD revenue forecast at $23,402,710,036, and the highest CRMD revenue forecast at $26,102,810,609. On average, 9 Wall Street analysts forecast CRMD's revenue for 2026 to be $35,141,489,851, with the lowest CRMD revenue forecast at $23,017,431,606, and the highest CRMD revenue forecast at $41,612,434,117.
In 2027, CRMD is forecast to generate $33,380,554,695 in revenue, with the lowest revenue forecast at $20,453,636,082 and the highest revenue forecast at $41,224,004,125.